ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ORGO Organogenesis Holdings Inc

4.945
-0.125 (-2.47%)
Last Updated: 18:11:47
Delayed by 15 minutes
Share Name Share Symbol Market Type
Organogenesis Holdings Inc NASDAQ:ORGO NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.125 -2.47% 4.945 4.94 4.95 5.115 4.915 4.97 464,696 18:11:47

Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025

27/01/2025 12:30pm

GlobeNewswire Inc.


Organogenesis (NASDAQ:ORGO)
Historical Stock Chart


From Jan 2025 to Mar 2025

Click Here for more Organogenesis Charts.

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2024 financial results will be reported after the market closes on Thursday, February 27th.

Management will host a conference call at 5:00 p.m. Eastern Time on February 27th to discuss the results of the quarter and fiscal year, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.

About Organogenesis Holdings Inc. Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.

Investor Inquiries:
ICR Healthcare
Mike Piccinino, CFA
OrganoIR@icrinc.com

Press and Media Inquiries:
Organogenesis
communications@organo.com

1 Year Organogenesis Chart

1 Year Organogenesis Chart

1 Month Organogenesis Chart

1 Month Organogenesis Chart